Eiko Lifesciences Ltd Stock Price Today (NSE: EIKO)
Fundamental Score
Eiko Lifesciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Eiko Lifesciences Ltd share price today is ₹49.74, down 3.48% on NSE/BSE as of 30 March 2026. Eiko Lifesciences Ltd (EIKO) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹69.89 (Cr). The 52-week high for EIKO share price is ₹65.90 and the 52-week low is ₹46.49. At a P/E ratio of 21.63x, EIKO is currently trading below its industry average P/E of 29.20x.
Eiko Lifesciences Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Eiko Lifesciences Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Eiko Lifesciences Share Price: A Financial Analysis
Specialty chemicals, unlike commodity chemicals, command higher margins and are less sensitive to economic cycles due to their application-specific formulations. This makes a deep dive into companies like Eiko Lifesciences crucial. This financial analysis focuses on the Eiko Lifesciences share price, currently at ₹51.110001, and examines its stability and potential risks based on publicly available information. The analysis considers its Price-to-Earnings (PE) ratio of 21.63 and the absence of Return on Capital Employed (ROCE) data.
A PE ratio of 21.63 suggests that investors are paying ₹21.63 for every rupee of Eiko Lifesciences' earnings. This ratio needs to be contextualized against its peers. Comparing Eiko Lifesciences Ltd with peers like
Amal regarding management quality, specifically their capital allocation track record, is crucial. Has Amal demonstrated superior skill in reinvesting profits for future growth, justifying a potentially higher valuation? This is an area requiring further investigation via detailed qualitative analysis.The absence of a reported ROCE figure (None%) is a significant red flag. ROCE measures how efficiently a company generates profits from its capital employed. A missing or negligible ROCE might indicate poor capital allocation, inefficient operations, or even questionable accounting practices. Without a positive ROCE, it is difficult to assess Eiko Lifesciences' ability to generate sustainable returns for its investors. This impacts the company's moat, its ability to defend its market share and profitability from competitors. A company that cannot efficiently utilize capital lacks a strong economic moat.
In conclusion, the current Eiko Lifesciences share price presents a complex picture. The PE ratio, while seemingly within a reasonable range, must be viewed alongside the missing ROCE data. A thorough review of its operational efficiency, debt levels, and competitive landscape, benchmarked against companies such as Bhatia Colour and Deep Polymers, is essential for any investor. This analysis is part of a comprehensive 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a more in-depth understanding of Eiko Lifesciences' financial health. This analysis is purely observational and does not constitute financial advice or a recommendation to buy or sell shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Eiko Lifesciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EIKO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Attractive Valuation (P/E: 21.63 vs Industry: 29.20)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (285.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (43.01%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (29.35% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (20.61% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (20.84x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Eiko Lifesciences Ltd Financial Statements
Comprehensive financial data for Eiko Lifesciences Ltd including income statement, balance sheet and cash flow
About EIKO (Eiko Lifesciences Ltd)
Eiko Lifesciences Ltd is a dynamic force in the specialty chemicals arena, meticulously crafting high-value ingredients and solutions for diverse global industries. Focused on prec...ision and innovation, EIKO leverages cutting-edge research and development to synthesize complex molecules, catering to niche applications where quality and performance are paramount. From specialized agrochemical components that enhance crop yields to advanced pharmaceutical intermediates that accelerate drug discovery, EIKO's comprehensive portfolio is designed to meet the evolving needs of its discerning clientele. The company prides itself on its commitment to sustainable practices, employing green chemistry principles to minimize environmental impact throughout its manufacturing processes. EIKO's strategic divisions synergistically operate, contributing to a robust and vertically integrated business model. The agrochemical division develops novel chemistries for crop protection, while the pharmaceutical arm synthesizes critical intermediates for drug formulations. EIKO's foray into oleo chemicals allows the company to offer bio-based solutions derived from natural oils and fats. In food additives, the organization is actively in manufacturing high-quality ingredients to boost and improve food production. Moreover, the company's dedication extends beyond production, encompassing comprehensive services such as research, development, logistics, and efficient distribution channels. This holistic approach ensures seamless delivery of tailored solutions to clients across geographical boundaries. Driven by a customer-centric philosophy, EIKO invests heavily in building strong, collaborative partnerships. The company's team of experienced chemists and engineers works closely with clients, providing technical support, customized formulations, and reliable supply chain management. EIKO's commitment to quality is unwavering, adhering to stringent regulatory standards and employing rigorous quality control measures at every stage of production. Through continuous innovation, operational excellence, and a steadfast dedication to customer satisfaction, EIKO is poised to further solidify its position as a trusted and reliable provider of specialty chemicals worldwide.
Company Details
Key Leadership
Corporate Events
Latest News
EIKO Share Price: Frequently Asked Questions
What is the current share price of Eiko Lifesciences Ltd (EIKO)?
As of 30 Mar 2026, 12:02 pm IST, Eiko Lifesciences Ltd share price is ₹49.74. The EIKO stock has a market capitalisation of ₹69.89 (Cr) on NSE/BSE.
Is EIKO share price Overvalued or Undervalued?
EIKO share price is currently trading at a P/E ratio of 21.63x, compared to the industry average of 29.20x. Based on this relative valuation, the Eiko Lifesciences Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of EIKO share price?
The 52-week high of EIKO share price is ₹65.90 and the 52-week low is ₹46.49. These values are updated daily from NSE/BSE price data.
What factors affect the Eiko Lifesciences Ltd share price?
Key factors influencing EIKO share price include quarterly earnings growth (Sales Growth: 43.01%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Eiko Lifesciences Ltd a good stock for long-term investment?
Eiko Lifesciences Ltd shows a 5-year Profit Growth of 25.18% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in EIKO shares.
How does Eiko Lifesciences Ltd compare with its industry peers?
Eiko Lifesciences Ltd competes with major peers in the Specialty Chemicals. Investors should compare EIKO share price P/E of 21.63x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of EIKO and what does it mean?
EIKO share price has a P/E ratio of 21.63x compared to the industry average of 29.20x. Investors pay ₹22 for every ₹1 of annual earnings.
How is EIKO performing according to Bull Run's analysis?
EIKO has a Bull Run fundamental score of 51/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does EIKO belong to?
EIKO operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Eiko Lifesciences Ltd share price.
What is Return on Equity (ROE) and why is it important for EIKO?
EIKO has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Eiko Lifesciences Ltd generates profits from shareholders capital.
How is EIKO debt-to-equity ratio and what does it indicate?
EIKO has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is EIKO dividend yield and is it a good dividend stock?
EIKO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Eiko Lifesciences Ltd shares.
How has EIKO share price grown over the past 5 years?
EIKO has achieved 5-year growth rates of: Sales Growth 29.35%, Profit Growth 25.18%, and EPS Growth 20.61%.
What is the promoter holding in EIKO and why does it matter?
Promoters hold 37.17% of EIKO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Eiko Lifesciences Ltd.
What is EIKO market capitalisation category?
EIKO has a market capitalisation of ₹70 crores, placing it in the Small-cap category.
How volatile is EIKO stock?
EIKO has a beta of N/A. A beta > 1 suggests the Eiko Lifesciences Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is EIKO operating profit margin trend?
EIKO has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is EIKO quarterly performance?
Recent quarterly performance shows Eiko Lifesciences Ltd YoY Sales Growth of 43.01% and YoY Profit Growth of 285.71%.
What is the institutional holding pattern in EIKO?
EIKO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Eiko Lifesciences Ltd stock.